Pancreatic cancer (Q57423198)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Pancreatic cancer	article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

1 reference

Europe PubMed Central

Pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

Carlo La Vecchia

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

John P Neoptolemos

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

Ralph H. Hruban

10

object named as

Ralph H Hruban

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

9

object named as

David A Tuveson

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

Margaret Tempero

8

object named as

Margaret Tempero

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

3

object named as

Minoti Apte

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

7

object named as

Rachel E Neale

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

author name string

Murray Korc

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

Colin D Johnson

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

publication date

21 April 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

Nature Reviews Disease Primers

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

1

0 references

16022

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

2564 resected periampullary adenocarcinomas at a single institution: trends over three decades

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Population attributable risk for pancreatic cancer in Northern Italy.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

2. Tobacco-attributable cancer burden in the UK in 2010

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Cancers in Australia in 2010 attributable to modifiable factors: introduction and overview

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Smokeless tobacco and cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Physical activity and risk of pancreatic cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Nutrient-based dietary patterns and pancreatic cancer risk

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Coffee and cancer of the pancreas

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4)

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Family history of cancer and the risk of cancer: a network of case–control studies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Genetics and biology of pancreatic ductal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Thirty years of experience with intraductal papillary mucinous neoplasm of the pancreas: from discovery to international consensus

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Signaling pathways in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Common activation of canonical Wnt signaling in pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Whole genomes redefine the mutational landscape of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Genomic analyses identify molecular subtypes of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer genomics

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Signatures of mutational processes in human cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Genetic mutations associated with cigarette smoking in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer stroma: friend or foe?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Subtyping Pancreatic Cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Gene signatures from pancreatic cancer tumor and stromal cells predict disease outcome

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Dynamics of the immune reaction to pancreatic cancer from inception to invasion

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Complex role for the immune system in initiation and progression of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A starring role for stellate cells in the pancreatic cancer microenvironment

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Role of pancreatic stellate cells in pancreatic cancer metastasis.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Activated pancreatic stellate cells sequester CD8 T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

High expression of Galectin‐1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic stellate cells reduce insulin expression and induce apoptosis in pancreatic β-cells

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Stromal response to Hedgehog signaling restrains pancreatic cancer progression

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Hypoxia signaling pathways: modulators of oxygen-related organelles

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancers require autophagy for tumor growth

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

p53 status determines the role of autophagy in pancreatic tumour development

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult Mice

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Organoid models of human and mouse ductal pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A modular and flexible ESC-based mouse model of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer-induced cachexia is Jak2-dependent in mice

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

TLR9 ligation in pancreatic stellate cells promotes tumorigenesis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80( ) Extratumoral Macrophages

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Plectin-1 as a novel biomarker for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A mouse to human search for plasma proteome changes associated with pancreatic tumor development

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Detection of circulating tumor DNA in early- and late-stage human malignancies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8 T cell induction and reduction in the frequency of CD4 foxp3 ICOS- regulatory T cells.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Recent progress in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Imaging diagnosis of pancreatic cancer: a state-of-the-art review

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Current evidence for the diagnostic value of gadoxetic acid-enhanced magnetic resonance imaging for liver metastasis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

New insights into pancreatic cancer-induced paraneoplastic diabetes

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Survival after Resection for Invasive Intraductal Papillary Mucinous Neoplasm and for Pancreatic Adenocarcinoma: A Multi-Institutional Comparison According to American Joint Committee on Cancer Stage

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Early detection of sporadic pancreatic cancer: summative review

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Screening for pancreatic cancer in a high-risk cohort: an eight-year experience

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

National failure to operate on early stage pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer surgery in the new millennium: better prediction of outcome

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

One thousand consecutive pancreaticoduodenectomies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Total pancreatectomy for primary pancreatic neoplasms: renaissance of an unpopular operation

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A systematic review and meta-analysis of laparoscopic versus open distal pancreatectomy for benign and malignant lesions of the pancreas: it's time to randomize

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Minimally-invasive vs open pancreaticoduodenectomy: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

A systematic review on robotic pancreaticoduodenectomy.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

250 robotic pancreatic resections: safety and feasibility

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Distal pancreatectomy with celiac axis resection: what are the added risks?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Modified Appleby procedure for resection of tumors of the pancreatic body and tail with celiac axis involvement

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Extended Versus Standard Lymphadenectomy for Pancreatic Head Cancer: Meta-Analysis of Randomized Controlled Trials

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Resection of primary pancreatic cancer and liver metastasis: a systematic review

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Palliative resections versus palliative bypass procedures in pancreatic cancer—a systematic review

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Meta-analysis of radical resection rates and margin assessment in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Most Pancreatic Cancer Resections are R1 Resections

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Definition of microscopic tumor clearance (r0) in pancreatic cancer resections

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer: surgery alone is not sufficient

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The needs of patients with advanced, incurable cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Quality of life and outcomes after pancreaticoduodenectomy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The Role of End-of-Life Issues in the Design and Reporting of Cancer Clinical Trials: A Structured Literature Review

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Patient-centric trials for therapeutic development in precision oncology.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Mining the genomes of exceptional responders

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Pancreatic cancer microenvironment

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Postoperative pancreatic fistula: an international study group (ISGPF) definition.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Randomized, Double-Blind, Controlled Trial of Early Endoscopic Ultrasound–Guided Celiac Plexus Neurolysis to Prevent Pain Progression in Patients With Newly Diagnosed, Painful, Inoperable Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Predictors of survival in patients with malignant gastric outlet obstruction: A patient-oriented decision approach for palliative treatment

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Stent treatment of malignant gastric outlet obstruction: the effect on rate of gastric emptying, symptoms, and survival

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Current and future care of patients with the cancer anorexia-cachexia syndrome

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Anti-cancer effects of oncolytic viral therapy combined with photodynamic therapy in human pancreatic cancer cell lines

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The EGF receptor family: spearheading a merger of signaling and therapeutics

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Molecular genetics and related developments in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Targeting lactate metabolism for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Serum fatty acid synthase as a marker of pancreatic neoplasia

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Very high risk of cancer in familial Peutz-Jeghers syndrome

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Clinical and genetic characteristics of hereditary pancreatitis in Europe

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds withp16INK4Mutations

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Risk of pancreatic cancer in families with Lynch syndrome

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Risk of pancreatic cancer in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Cancer risks in BRCA2 mutation carriers

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Cancer risk in heterozygotes for ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

31 March 2020

The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting cancer cell metabolism in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038/NRDP.2016.22

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/NRDP.2016.22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27158978 AND SRC:MED&resulttype=core&format=json

4 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57423198&oldid=2213461881"